Clinical Trial

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia). A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07252440
Lead Sponsor Shanghai Auzone Biological Technology Co., Ltd.
Conditions AD, Early Alzheimer's Disease
Enrollment 180 participants
Start Date 2025-12-19
Primary Completion 2028-10-23 (estimated)
Study Completion 2028-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-16